Quince Therapeutics announced an agreement to acquire Orphai in a transaction paired with a substantial private financing intended to support expansion of its pulmonary-focused pipeline. The deal adds Orphai’s respiratory assets and related expertise to Quince’s portfolio, with management positioning the transaction as a way to accelerate development of programs targeting serious pulmonary diseases. Orphai’s platform and lead candidates are expected to be integrated into Quince’s existing R&D infrastructure following closing.
In conjunction with the acquisition, Quince disclosed a planned private placement of up to 187 million dollars, backed by a syndicate of healthcare-focused investors. Proceeds are earmarked primarily for advancing the combined company’s pulmonary programs through key clinical and regulatory milestones, as well as for general corporate purposes. Quince stated that the financing is expected to extend its cash runway and provide flexibility to progress multiple assets in parallel.
The acquisition and financing are subject to customary closing conditions, including regulatory clearances where applicable. Quince indicated that it will provide further updates on integration plans and pipeline timelines following completion of the transaction and close of the private placement.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!